Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration. by Giannakaki-Zimmermann, Helena et al.
E-Mail karger@karger.com
 Original Paper 
 Ophthalmologica 
 DOI: 10.1159/000452929 
 Outcomes when Switching from a pro re nata 
Regimen to a Treat and Extend Regimen Using 
Aflibercept in Neovascular Age-Related Macular 
Degeneration 
 Helena Giannakaki-Zimmermann    Andreas Ebneter    Marion R. Munk    
Sebastian Wolf    Martin S. Zinkernagel  
 Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern,  Bern , Switzerland
 
 Introduction 
 Antiangiogenic agents have revolutionized the treat-
ment of wet age-related macular degeneration (AMD) in 
the last decades. However, the initial enthusiasm for this 
treatment has been dampened by the need of monthly 
injections to obtain good functional outcomes. To avoid 
the associated treatment burden for patients and related 
health care costs, alternative treatment regimens were de-
veloped to reduce the number of injections needed. Pro 
re nata (PRN) or treat as needed is one of the attempts to 
lower the number of injections while trying to obtain 
good functional outcomes in terms of best-corrected vi-
sual acuity (BCVA). Several studies, such as the CATT 
and the IVAN trials, showed that a PRN regimen required 
up to 50% fewer injections compared to a monthly regi-
men  [1] ; however, PRN was shown to lead to marginally 
inferior functional outcomes  [2–4] and less reduction of 
central retinal thickness (CRT) compared to monthly in-
jections  [1] . One disadvantage for both, the PRN and for 
the monthly regimen is the need for monthly visits. A 
more recently introduced strategy to optimize the 
benefit:risk ratio is the treat and extend regimen (TER), 
which usually involves fixed treatment intervals until 
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 Abstract 
 Purpose: To investigate outcomes in patients with neovas-
cular age-related macular degeneration (AMD) switched 
from a pro re nata regimen (PRN) to a treat and extend regi-
men (TER) under aflibercept.  Procedure: Thirty-two patients 
were observed over 2 years: the first year on PRN and the 
second year on TER. Best-corrected visual acuity (BCVA) and 
central retinal thickness (CRT) were evaluated. Intra- and 
subretinal fluid as well as the number of visits and injections 
were assessed.  Results: Both regimens resulted in a stable 
BCVA. Patients in TER had a significant decrease of CRT after 
1 year compared to 1 year of treatment on PRN ( p < 0.0001). 
TER resulted in significantly less visits; however, significantly 
more injections were observed over the course of 1 year 
compared to PRN (10.25 vs. 7.5,  p < 0.0001 and 5.97 vs. 7.5,
 p = 0.0002, respectively).  Conclusion: A switch from PRN to 
TER in patients treated with aflibercept for AMD appears to 
be safe.  © 2016 S. Karger AG, Basel 
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clinical remission is seen in optical coherence tomogra-
phy (OCT), followed by either extension or decrease of 
treatment intervals, depending on OCT results  [5, 6] . Al-
though there is a relative paucity of data on TER therapy, 
it has been adopted by the majority of AMD-treating phy-
sicians, mainly because it decreases the frequency of of-
fice visits while minimizing disease activity  [1] . A recent 
study compared ranibizumab to bevacizumab using a 
treat and extend protocol and found a comparable visual 
acuity (VA) after 1 year of treatment when compared to 
other clinical trials with monthly treatment  [7] . More-
over, patients with neovascular AMD and initially good 
visual function (20/40 or better) seem to show compara-
ble treatment results under TER after 2 years  [8] .
 However, there is little data on what to expect in real 
life when switching from PRN to TER. In our study, we 
compared functional and anatomical outcomes of pa-
tients under long-term therapy with anti-VEGF who have 
been switched from PRN to TER.
 Methods 
 Study Design and Patients 
 This was a 2-year observational, retrospective study at a ter-
tiary referral center.
 Patients over 50 years of age with choroidal neovascularization 
due to AMD with at least 2 years of continuous treatment with 
aflibercept were included. Within those 2 years, they had at least 1 
year of continuous anti-VEGF-therapy using PRN with aflibercept 
prior to the switch to TER, and they had at least 1 year of continu-
ous treatment under TER. The baseline of analysis was defined as 
the time point when the switch from PRN to TER occurred.
 Regimens 
 Pro re nata Regimen. Patients were seen on monthly intervals. 
However, as this was a retrospective study, some patients had lon-
ger intervals due to conflicting schedules. Disease activity was as-
sessed based on OCT. When there was evidence of hemorrhage, 
subretinal fluid (SRF), or intraretinal fluid (IRF) based on OCT, 
retreatment was applied; otherwise the patient was scheduled to be 
seen 4 weeks later.
 Treat and Extend Regimen. Patients were seen and treated ac-
cording to a treat and extend scheme. Extension of intervals were 
based on signs of activity in OCT. Stability was defined as no IRF 
or SRF, in which case the retreatment interval was extended by 2 
weeks. If there were signs of activity (hemorrhages, IRF, or SRF) 
the intervals were shortened by 1 week to a minimum of 4 weeks.
 Study Procedures 
 Medical records of patients with CNV secondary to neovas-
cular AMD were reviewed and analyzed retrospectively accord-
ing to the above-defined criteria. Patients identified from the 
procedure logs at the Department of Ophthalmology, University 
Hospital Bern, between November 1, 2012 and July 1, 2015, were 
reviewed. Patients who underwent intraocular surgery other than 
intravitreal injections were excluded. Ethics approval (KEK-No. 
093/13) to conduct this study was obtained from the local ethics 
committee, and the study was performed in accordance with 
ICH-GCP guidelines. The need for written consent from each 
individual patient was waived because of the retrospective nature 
of the study.
 BCVA and the assessment of IRF and SRF were performed by 
physicians. Distance BCVA was tested using ETDRS charts, and 
the  BCVA letter score was collected. CRT was measured using 
Spectralis SD-OCT (Heidelberg Engineering, Heidelberg, Germa-
ny; Software version 5.3). Scans were acquired using an established 
protocol consisting of volume scans. For the volume scan of 20° × 
20°, 49 frames spaced 121 μm and each consisting of 512 A-scans 
were acquired. The automated real time was set between 6 and 12 
to reduce noise. The primary end point of the study was BCVA. 
Secondary end points were CRT, subretinal fluid and IRF, as well 
as the numbers of aflibercept injections and visits.
 Statistical Analysis 
 Data were collected in tables and statistical analysis was per-
formed using the Prism GraphPad ® commercial software package 
(Prism 6; GraphPad Software Inc., La Jolla, CA, USA). Data were 
analyzed using a paired  t test. For all analyses,  p < 0.05 was consid-
ered statistically significant. At each timeline, the different catego-
ries were tested for the mean value and standard deviation and 
compared to each other.
 Results 
 General Data 
 Thirty-two patients met our inclusion criteria and 
were included in this retrospective study (24 female and 
8 male patients). The mean age was 79.3 years (±9.5 SD).
All patients had received previous treatment with anti-
VEGF agents and were on a long-term treatment course 
with anti-VEGF agents under PRN, with an average treat-
ment time of 236.1 ± 95.3 weeks (or 4.5 years) prior to the 
switch from PRN to TER.
 During the observation time, none of the patients un-
der examination underwent cataract surgery.
 Visual Acuity 
 During the first year of our study, patients on PRN 
treatment showed a stable VA (initial BCVA: 64.0 ± 15.2; 
end point BCVA: 64.0 ± 16.1). The mean change in VA 
was –0.52 letters in the PRN group and –0.65 letters in the 
TER group compared to baseline ( Fig. 1 ).
 CRT, IRF, and SRF 
 Patients after 1 year of TER treatment had a significant 
thinner retina (end point: 288 ± 60 μm) compared to 1 
year of treatment using PRN (baseline: 330 ± 89 μm; ini-
tial CRT: 358 ± 107 μm) ( p < 0.0001). The mean change 
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in CRT was 3.02 μm in the PRN group and –25 μm in the 
TER group compared to baseline.
 IRF and SRF showed significant changes when switching 
to TER; both, the percentage of patients with IRF and/or 
SRF decreased when switching to TER. While 56% of the 
patients showed IRF at the beginning of the study (time 
point: –52 weeks), 49% had IRF after 1 year of PRN (base-
line), and 34% had IRF after 1 year of TER (+52 weeks,  p < 
0.0001). At the start of the observation period, 63% had 
SRF. After 1 year of treatment with PRN, the percentage of 
patients having SRF was unchanged and still at 62%, but 
was reduced to 50% after 1 year on TER ( p < 0.0001).
 Table 1. OCT characteristics of patients who lost VA of more than 4 letters on the ETDRS chart
PRN TER
Patients who lost ≥4 letters on the ETDRS chart, n (%) 8 (25) 12 (37.5)
Gender, %
Female 62.5 66.67
Male 37.5 33.33
Mean age, years 77.25 77.0
Increase of IRF, % 12.5 33.3
Increase of SRF, % 25 16.67
Increase of IRF and SRF, % 12.5 0
Increase of RPE atrophy, % 0 16.67
Increase of subretinal fibrosis, % 0 8.33
Opacification of refractive media, % 12.5 0
No differences/worsening in OCT to determine, % 37.5 25
 PRN, pro re nata regimen; TER, treat and extend regimen; ETDRS, Early Treatment Diabetic Retinopathy 
Study; OCT, ocular coherence tomography; RPE, retinal pigment epithelium.
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 Fig. 1.  a Representative OCT images at the beginning of PRN treat-
ment (upper OCT image), at baseline, when the switch of treat-
ment regimens took place (middle OCT image), and after 1 year of 
TER treatment (lower OCT image).  b ,  c Development of BCVA 
(upper graph) and CRT (lower graph) over 2 years with a switch 
of treatment regimen at baseline (BL). The values on the left side 
of the BL were recorded within the PRN; whereas on the right side 
of the BL, TER values are shown. OCT, optical coherence tomog-
raphy; PRN, pro re nata regimen; TER, treat and extend regimen; 
CRT, central retinal thickness. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 B
er
n 
   
   
   
   
   
   
   
   
   
   
   
   
  
13
0.
92
.1
75
.1
66
 - 
1/
9/
20
17
 2
:5
5:
20
 P
M
 Giannakaki-Zimmermann et al.
 
Ophthalmologica
DOI: 10.1159/000452929
4
 Subgroups of Patients Who Lost VA 
 Next, we investigated those patients who lost VA dur-
ing the whole observational period ( ≥ 4 letters on the
ETDRS reading chart). We identified 20 patients (8 pa-
tients during PRN and 12 patients during TER) and re-
corded the changes seen on OCT and slit-lamp exam of 
visits where VA dropped ( Table 1 ).
 Number of Injections and Visits 
 The total number of injections in the PRN timeline 
group was 5.97 ± 1.85 versus 7.5 ± 2.47 in the TER time-
line group ( p = 0.0002). The number of visits was 10.25 ± 
2.59 in the PRN period versus 7.5 ± 2.51 in the TER pe-
riod ( p = < 0.0001) ( Fig. 2 b).
 Discussion 
 The results of our study show that patients being treat-
ed with aflibercept on PRN for 1 year and then being 
switched to TER recorded comparable visual outcomes. 
However, while the PRN group received fewer injections, 
the TER group underwent fewer visits and had a signifi-
cantly decreased CRT after 1 year of treatment.
 The change of VA in both regimen groups was similar. 
A marginal drop of approximately 2 ETDRS letters was 
seen in the TER period. This may be explained by the nat-
ural course of the disease as these patients had already 
been treated for an average of 2.5 years before being in-
cluded into this study. Prünte et al.  [9]  performed a similar 
study in neovascular AMD patients receiving ranibizu-
mab and evaluated the effect of switching from PRN to 
TER in a clinical routine setting employing a similar TER 
protocol. Interestingly, with a similar mean treatment in-
terval of 7.1 ± 2.3 weeks, they found a significant improve-
ment of the Snellen BCVA after 1 year of TER (0.47 ± 0.22 
to 0.55 ± 0.23), which is in contrast to our findings. This 
disagreement may be explained by divergent disease dura-
tions of the included patients or by the duration between 
the last injection on PRN and the first injection on TER.
 Although the CRT decreased in the PRN period from 
358 ± 106 to 330 ± 89 μm, CRT further decreased during 
the TER period. A recent retrospective study analyzing 
separately PRN and TER cohorts showed a similar de-
crease in CRT compared to baseline over a period of 3 
years  [10] .
 In our study, both the presence of IRF and SRF was 
significantly different in both treatment regimens. When 
treatment was switched from PRN to TER, patients 
showed less fluid in the TER arm (IRF 49 vs. 34%, SRF 63 
vs. 50%). Fung et al.  [11]  found comparable results with 
50% SRF and 50% IRF after 12 months of TER using 0.5 
mg of intravitreal ranibizumab. Nevertheless, aside from 
our study, there are so far no systematic analyses on IRF 
and SRF during treatment with TER compared to PRN. 
However, the goal of TER is to achieve and maintain a 
“dry” macula by gradually increasing the length of time 
between injections in the absence of macular fluid  [5, 10] ; 
therefore, our findings underscore this principle.
 Similar to the findings of other reports  [10, 12] , pa-
tients undergoing antiangiogenic therapy according to 
the TER dosing scheme received statistically more injec-
tions compared to PRN. The mean number of injections 
our patients received was 7.5 ± 2.47 in the TER compared 
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 Fig. 2.  a The percentage of patients having either SRF or IRF over 
the course of 2 years with a switch of treatment regimen from PRN 
to TER at baseline (BL) is shown.  b Column graphs depicting the 
number of injections (black columns) and the number of visits 
(grey columns) in the PRN and the TER group, respectively. SRF, 
subretinal fluid; IRF, intraretinal fluid; PRN, pro re nata regimen; 
TER, treat and extend regimen. 
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to 5.97 ± 1.8 in the PRN. In 1 report, the difference of both 
groups was recorded as follows: 7.8 ± 1.3 injections in the 
TER versus 5.2 ± 1.9 injections in the PRN group  [12] . 
Beside the so far mentioned papers, several other studies 
were conducted to evaluate the efficacy of TER in neovas-
cular AMD using ranibizumab and bevacizumab  [7, 13–
16] . Different TER protocols were applied in respective 
studies but most of them increased the treatment inter-
vals by 2 weeks per visit, unless evidence for disease activ-
ity was present. A recent literature review summarized 
the so far conducted TER studies  [17] . Based on these 
studies, a recommended TER algorithm was established, 
defining disease stability, disease activity, and addressing 
the extension interval. The consensus panel agreed on an 
extension interval of 2 weeks if neovascular AMD was 
stable. In cases of disease activity, the interval should be 
shortened by 1–2 week. In cases of severe disease activity, 
a re-induction of monthly treatment should be consid-
ered  [17] . Our study employed the recommended TER 
algorithm and therefore gives valid insight into the poten-
IVT IVT
IVT
AMD
IVT
b
Yes
Yes
No
No
min. 4 weeks
max. 16 weeks4
weeks
6
weeks
–1
weeks
+2
weeksActive
Active
IVT
1st visit – Eylea 1st visit – Eylea
2nd visit – Eylea
3rd visit – Eylea
200 μm
2nd visit – no injection
3rd visit – Eylea
Baseline – Eylea
a
1 month 1 month
Active
Not
active
Control examination Control examination
 Fig. 3.  a Flowchart of PRN treatment (top) and OCT images (bot-
tom) acquired monthly during PRN treatment. An intravitreal in-
jection of Eylea was carried out on every second month. The OCT 
image in the middle shows the baseline time point when the regi-
men was switched from PRN to TER. In total, the patient received 
7 injections of Eylea and had 11 office visits during the year on PRN 
treatment. The patient received 4 injections of Lucentis prior to the 
start of PRN with Eylea.  b Flowchart of TER treatment (top) and 
OCT images on TER (bottom). In total, the patient received 9 in-
jections of Eylea and had the same amount of office visits during 
that treatment regimen year. OCT, optical coherence tomography; 
PRN, pro re nata regimen; TER, treat and extend regimen. 
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tial benefit when switching from PRN to TER in a routine 
clinical setting ( Fig. 3 ).
 Our study bears several weaknesses, mainly due to its 
retrospective nature and the relatively low number of pa-
tients included. The retrospective design and the “real-
world” setting led to visit intervals that were not strictly 4 
weekly on PRN, resulting in fewer visits than expected. 
Generally, the follow-up intervals in TER were better ad-
hered to compared to PRN. Maybe an interval of 4 weeks 
in the PRN group, as recommended, is not always easy to 
follow, as it may collide with holidays or other medical ap-
pointments in cases of other systemic diseases. Further-
more, because patients were switched from PRN to TER, 
there is likely to have been more disease progression in the 
period when TER was applied, which should be considered 
when assessing the characteristics associated with a signif-
icant VA loss under both treatment regimens. Nonetheless, 
we did not observe any severe recurrence, such as large sub-
retinal bleeding, in between visits within the TER group.
 In conclusion, our cohort showed no significant 
changes in BCVA when switched from PRN to TER. 
However, the CRT was significantly decreased and there 
were significantly less patients having IRF and/or SRF. In 
addition, significantly less visits were observed in the 
TER period, which may also arise from the fact that TER 
offers individualized and flexible treatment plans and in-
tervals.
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